Free Trial
→ Stunning new initiative unfolding in the White House? (From Paradigm Press) (Ad)tc pixel

Ampliphi Biosciences (NYSEAMERICAN:APHB) Shares Down 0.7% - Time to Sell?

Written by MarketBeat
Updated September 20, 2025
Ampliphi Biosciences logo with Medical background

Key Points

  • Ampliphi Biosciences shares fell by 0.7%, trading as low as $2.86 and last at $2.94, significantly below its typical volume with only 6,009 shares traded.
  • The company focuses on developing therapies for antibiotic-resistant infections using bacteriophage-based technology.
  • Ampliphi has two primary therapies in development: AB-SA01 for staphylococcus aureus infections and AB-PA01 for pseudomonas aeruginosa infections.
  • Five stocks we like better than Ampliphi Biosciences.

Ampliphi Biosciences Corp (NYSEAMERICAN:APHB - Get Free Report)'s stock price was down 0.7% during mid-day trading on Tuesday . The company traded as low as $2.86 and last traded at $2.94. Approximately 6,009 shares were traded during trading, a decline of 99% from the average daily volume of 842,200 shares. The stock had previously closed at $2.96.

Ampliphi Biosciences Trading Up 3.0%

The business has a fifty day moving average price of $2.59 and a 200-day moving average price of $1.99.

About Ampliphi Biosciences

(Get Free Report)

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P.

Featured Stories

Should You Invest $1,000 in Ampliphi Biosciences Right Now?

Before you consider Ampliphi Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ampliphi Biosciences wasn't on the list.

While Ampliphi Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.